ReviewJournal of advanced research2026
Flavonoid-modulated JAK-STAT signaling mitigates malignant transformation and drug resistance in breast tumors: A clinically relevant 3PM-guided innovation.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Flavonoids as Modulators of the p53-Bcl-2 Axis in Cancer: Molecular Mechanisms and Therapeutic Implications.Pharmaceutics · 2026Review
- From Activity Screening to Quality Control: UHPLC-MS/MS Analysis of Anti-Inflammatory Cyclodipeptides inMolecules (Basel, Switzerland) · 2026Article
- Innovative mitochondria-based holistic 3PM approach to female health status: Facts and outlook.The EPMA journal · 2026Article
- Palmaturbine Inhibits Pancreatic Ductal Adenocarcinoma by Suppressing the JAK2/STAT3 Signaling Pathway.International journal of molecular sciences · 2026Article
- Luteolin and its derivatives: modulation of epithelial-mesenchymal transition in fibrosis and cancer.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) treatment efficacy is often compromised by tumor cell plasticity and multidrug resistance of multi-factorial origin. Among emerging therapeutic agents, flavonoids - a structurally diverse group of naturally occurring polyphenols - have demonstrated a significant potential to modulate the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway, a key driver of oncogenic transformation, immune evasion, and therapeutic failure in BC. Notably, natural compounds, including but not restricted to apigenin, quercetin, naringenin, morin, luteolin, butein, xanthohumol, silibinin, baicalein, nobiletin, rosmanol, orientin, eriocitrin, breviscapine, 8-hydroxydaidzein, icariside I, cardamonin, epigallocatechin-3-gallate, fisetin, brutieridin, melitidin, isoliquiritigenin, and sophoraflavanone G, have been recognized as potent JAK-STAT modulators in BC models. KEY SCIENTIFIC CONCEPTS OF THE STUDY: Through targeted interference with this pathway, flavonoids exert pleiotropic antitumor effects - enhancing the efficacy of chemotherapeutic agents, suppressing cellular proliferation and invasion, and reducing tumor aggressiveness. Beyond JAK-STAT signaling, flavonoids also influence several additional therapy resistance-related mechanisms, including regulation of ATP-binding cassette (ABC) transporters, promotion of apoptosis, suppression of epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs), cell cycle arrest, mitochondrial autophagy and mitophagy modulation, as well as remodeling of the tumor microenvironment. AIMS OF THE STUDY: This article provides a comprehensive overview of the molecular mechanisms by which flavonoids overcome therapeutic resistance in BC, focusing on JAK-STAT signaling modulation. The paper follows principles of Predictive, Preventive, and Personalized Medicine (3PM), promoting the paradigm shift from reactive to proactive medicine. Contextually, it underscores the importance of multidisciplinary research to elucidate flavonoid-specific mechanisms, identify predictive biomarker panels, and develop advanced delivery systems, integrates patient phenotyping, multi-level diagnostics, and AI-driven data interpretation to enable cost-effective primary and secondary prevention, and therapeutic algorithms tailored to personalised patient profiles improving therefore individual outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.